StockData

Foghorn Therapeutics vs Tango Therapeutics

FHTX and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FHTX and TNGX compare

Tango Therapeutics is the larger company, worth 34 times as much as Foghorn Therapeutics ($3.7B against $109M).

Tango Therapeutics grew revenue faster over the last twelve months (121% versus 52.0% for Foghorn Therapeutics).

Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of −176% compared with −230% at Tango Therapeutics.

Tango Therapeutics scores higher on the StockData Score (10 against 9 for Foghorn Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFHTXTNGX
Size and price
Market cap$109M$3.7B
Share price$1.83$22.11
Change, 1 year−61.0%171%
Change, 5 years−86.6%114%
Beta (5Y)2.821.67
Employees106137
StockData Score
Total score910 (better)
Valuation score1 (better)0
Growth score22
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S3.0× (better)69.3×
P/B–3.6×
FCF yield−77.6%−3.9% (better)
Fair value–$9.71
Margin of safety–−128%
Growth
Revenue growth (TTM)52.0%121% (better)
Revenue growth, 5Y average135% (better)52.1%
Profitability
Operating margin−198% (better)−253%
Net margin−176% (better)−230%
FCF margin−229% (better)−268%
Return on equity–−21.3%
Financial health
Debt / equity–0.00
Current ratio3.3650.82 (better)
Altman Z-score−4.6145.17 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions75.6%127%
Held by insiders36.3%11.7%
Insider net buying, 12 months–−$8.1M
Short interest, % of float6.0%32.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.